BOSTON–(BUSINESS WIRE)–Global growth equity investor Summit Partners today announced the addition of Davide Molho to the firm’s Executive-in-Residence (“EIR”) program. In this role, Dr. Molho will work closely with Summit’s healthcare & life sciences team to identify new investment opportunities and advise growth-stage companies focused on the development and commercialization of advanced therapies.
Dr. Molho, DVM, brings more than 25 years of international operational and business management experience in the contract research, life sciences, biotechnology and animal health industries. He joins Summit Partners’ EIR program from Viroclinics-DDL, a Summit-backed virology and immunology CRO, where he had served as CEO since 2020. During his tenure, Dr. Molho led Viroclinics-DDL through a period of significant growth and global expansion, culminating in the company’s sale to Cerba Healthcare in 2022. Prior to Viroclinics-DDL, Dr. Molho served as CEO of Evolution Research Group and spent nearly two decades with Charles River Laboratories, where eventually he served as President and Chief Operating Officer of the global organization.
“Davide is a high-caliber executive with an impressive record of leadership and a deep appreciation for the important mission that drives teams operating at the forefront of drug discovery and commercialization,” said Ross Stern, a Managing Director with Summit Partners. “We are thrilled to once again work with Davide and bring his perspective and experience to Summit’s EIR program.”
“At Viroclinics-DDL, I had the opportunity to work closely with the Summit team in scaling the business, enhancing our infrastructure, and expanding our global reach and capacity – all during a time when the vital role CROs play in accelerating the market entry of innovative vaccines and therapies has never been clearer,” said Dr. Molho. “I’ve experienced first-hand the resources and productive approach to partnership that the Summit team brings to growth businesses, and I’m proud to join Summit’s EIR program.”
Summit has been active in the healthcare and life sciences sector for nearly four decades. Since the firm’s founding in 1984, Summit has partnered with more than 100 companies across the healthcare services, healthcare IT and life sciences sectors.
Summit’s EIR program is an established element of the firm’s growth-oriented investing strategy. Since its inception, the program has facilitated collaboration between seasoned industry executives and Summit’s investment teams, working to identify sector-specific opportunities in which EIRs may support companies in an ongoing capacity through board or leadership roles.
About Summit Partners
Founded in 1984, Summit Partners is a global alternative investment firm that is currently managing more than $35 billion in capital dedicated to growth equity, fixed income and public equity opportunities. Summit Partners invests across growth sectors of the economy and has invested in more than 550 companies in healthcare and life sciences, technology and other growth industries. Summit Partners maintains offices in North America and Europe and invests in companies around the world. For more information, please see www.summitpartners.com or follow on LinkedIn.